利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.024 秒)

    Oligosaccharide biomarkers for mucopolysaccharidoses and other related disorders
    2.
    发明申请
    Oligosaccharide biomarkers for mucopolysaccharidoses and other related disorders 审中-公开
    低聚糖生物标志物用于粘多糖贮积症和其他相关疾病

    公开(公告)号：US20060286034A1

    公开(公告)日：2006-12-21

    申请号：US10517899

    申请日：2003-06-13

    申请人： Peter Meikle ,  Maria Fuller ,  Steven Ramsey ,  Enzo Ranieri ,  John Hopwood

    发明人： Peter Meikle ,  Maria Fuller ,  Steven Ramsey ,  Enzo Ranieri ,  John Hopwood

    IPC分类号： A61K49/00 ,  G01N33/53 ,  G01N33/00

    CPC分类号： G01N33/66 ,  G01N2400/40

    摘要： The present invention is related to methods for diagnosing mucopolysaccharidoses (“MPS”) and related diseases. This invention pertains to methods for identifying and quantitating biochemical markers (“biomarkers”) that are present in biological fluids or tissues of a patient having a MPS or related disorder. One aspect of the method comprises determining a target quantity of a target MPS biomarker oligosaccharide from a target biological sample taken from the target animal, and then comparing the target quantity to a reference quantity of a reference MPS biomarker oligosaccharide for the diagnosis, characterization, monitoring, and clinical management of MPS and related disease. This invention also describes a kit comprising a oligosaccharide derivatization solution; an acid solution; an internal standard; a solid phase extraction column; a solid phase extraction column wash solution; an oligosaccharide elution solution; and a set of instructions for using the kit to diagnose a MPS or related disease.

    摘要翻译： 本发明涉及用于诊断粘多糖贮积症（“MPS”）和相关疾病的方法。 本发明涉及用于鉴定和定量存在于具有MPS或相关病症的患者的生物流体或组织中的生化标志物（“生物标志物”）的方法。 该方法的一个方面包括从取自目标动物的目标生物样品中确定目标MPS生物标记寡糖的目标量，然后将目标量与参考MPS生物标记寡糖的参考量进行比较，以进行诊断，表征，监测 ，以及MPS及相关疾病的临床管理。 本发明还描述了一种包含寡糖衍生化溶液的试剂盒; 酸溶液; 内部标准; 固相萃取柱; 固相萃取柱洗涤液; 寡糖洗脱液; 以及使用该套件诊断MPS或相关疾病的一组说明。

    Multiplex screening for lysosomal sotrage disorders (lsds)
    5.
    发明申请
    Multiplex screening for lysosomal sotrage disorders (lsds) 失效
    多重筛选溶酶体动物障碍（lsds）

    公开(公告)号：US20070072243A1

    公开(公告)日：2007-03-29

    申请号：US10551396

    申请日：2004-03-31

    申请人： Peter Meikle ,  John Hopwood ,  Douglas Brooks ,  Caroline Dean

    发明人： Peter Meikle ,  John Hopwood ,  Douglas Brooks ,  Caroline Dean

    IPC分类号： G01N33/567 ,  G01N33/53

    CPC分类号： G01N33/543 ,  A61K49/0058 ,  A61K49/0091 ,  G01N33/54313 ,  G01N33/582 ,  G01N33/6893

    摘要： A novel protein profiling method of testing for Lysosomal Storage Diseases (“LSD”) using discovered normalized lysosomal fingerprint patterns. The fingerprint patterns reveal the health of lysosomal organelles, specific LSD, and clinical severity Multiplexing bead technology for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Compounds, reagents, and methods for identifying and quantifying multiple target enzymes and proteins.

    摘要翻译： 一种使用发现的归一化溶酶体指纹图谱测定溶酶体贮积病（“LSD”）的新型蛋白质分析方法。 指纹图谱揭示了溶酶体细胞器，特异性LSD和临床严重性的复合珠粒技术，用于同时筛选多种LSD并使测定的酶活性或蛋白质水平与其他溶酶体蛋白质，酶或酶活性正常化。 用于鉴定和定量多种靶酶和蛋白质的化合物，试剂和方法。

    Screening For Lysosomal Storage Disease Status
    6.
    发明申请
    Screening For Lysosomal Storage Disease Status 审中-公开
    筛选溶酶体贮积病状况

    公开(公告)号：US20080233655A1

    公开(公告)日：2008-09-25

    申请号：US10594699

    申请日：2005-03-31

    申请人： Peter Meikle ,  John Hopwood ,  Maria Fuller ,  Phillip Whitfield ,  Peter Sharp

    发明人： Peter Meikle ,  John Hopwood ,  Maria Fuller ,  Phillip Whitfield ,  Peter Sharp

    IPC分类号： G01N33/00

    CPC分类号： G01N33/92

    摘要： A method of ascertaining the LSD (Lysosomal storage disorder) status of an individual comprising taking a tissue or body fluid sample from the individual and estimating a level in the sample of each of three or more compound indicators. The indicators reflect the level of respectively each of three or more lipid containing storage associated compounds. The levels are used to calculate an LSD index number which is then compared with a standard to provide an assessment of the LSD status of the individual. The indicator compounds are conveniently phospholipids, glycolipids or lipopolysaccharide species measured by mass spectrometry. The method may be used to ascertain the nature of the disorder from which the individual stuffers, and its severity. It may also be used to monitor the progress of treatment and to ascertain the prospects of an individual contracting an LSD by providing a subclinical indicators for the condition.

    摘要翻译： 确定个体的LSD（溶酶体储存障碍）状态的方法，包括从个体取组织或体液样品并估计三个或更多个化合物指示剂中每一个的样品中的水平。 这些指标反映了三种或更多种与脂质相关的化合物中各自的水平。 水平用于计算LSD指数，然后将其与标准进行比较，以提供个体的LSD状态的评估。 指示剂化合物方便地通过质谱法测量磷脂，糖脂或脂多糖物质。 该方法可以用于确定个体填充物的病症的性质及其严重性。 它还可用于监测治疗进展情况，并通过为病情提供亚临床指标来确定个体承包LSD的前景。

    Multiplex-bead complex for determination of Lysosomal Storage Disorders
    7.
    发明申请
    Multiplex-bead complex for determination of Lysosomal Storage Disorders 失效
    用于测定溶酶体储存障碍的多重珠复合物

    公开(公告)号：US20070265432A1

    公开(公告)日：2007-11-15

    申请号：US11291621

    申请日：2005-12-01

    申请人： Peter Meikle ,  John Hopwood ,  Douglas Brooks ,  Caroline Dean

    发明人： Peter Meikle ,  John Hopwood ,  Douglas Brooks ,  Caroline Dean

    IPC分类号： C07K16/18

    CPC分类号： G01N33/54313 ,  C07K16/18 ,  C07K16/2896 ,  G01N2333/916 ,  G01N2333/924

    摘要： Multiplexing bead technology is used for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Diagnostic compositions include microspheres conjugated to purified antibodies that specifically bind LSD target antigens: saposin, LAMP-1, α-iduronidase, α-glucosidase, β-glucosidase, 2-sulphatase, 4-sulphatase, α-galactosidase, sphingomyelinase, 3-sulphatase or sulphamidase. The target antigens are naturally present in biological fluids or tissues of either LSD or non-LSD patients.

    摘要翻译： 多重珠粒技术用于同时筛选多种LSD，并将测定的酶活性或蛋白质水平与其他溶酶体蛋白质，酶或酶活性标准化。 诊断组合物包括与纯化抗体结合的微球，其特异性结合LSD靶抗原：皂角蛋白，LAMP-1，α-艾杜糖酶，α-葡糖苷酶，β-葡糖苷酶，2-硫酸酯酶，4-硫酸酯酶，α-半乳糖苷酶，鞘磷脂酶，3-硫酸酯酶 或磺酰胺酶。 目标抗原天然存在于LSD或非LSD患者的生物流体或组织中。